49 related articles for article (PubMed ID: 36357573)
1. A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies.
Shepherd A; Bennychen B; Marcil A; Bloemberg D; Pon RA; Weeratna RD; McComb S
PLoS One; 2023; 18(6):e0273884. PubMed ID: 37347762
[TBL] [Abstract][Full Text] [Related]
2. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.
Cheng P; Chen X; Dalton R; Calescibetta A; So T; Gilvary D; Ward G; Smith V; Eckard S; Fox JA; Guenot J; Markowitz J; Cleveland JL; Wright KL; List AF; Wei S; Eksioglu EA
Mol Ther; 2022 Jun; 30(6):2315-2326. PubMed ID: 35150889
[TBL] [Abstract][Full Text] [Related]
3. Computational simulations of bispecific T cell engagers by a multiscale model.
Su Z; Almo SC; Wu Y
Biophys J; 2024 Jan; 123(2):235-247. PubMed ID: 38102828
[TBL] [Abstract][Full Text] [Related]
4. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry.
Shajan I; Rochet LNC; Tracey SR; Jackowska B; Benazza R; Hernandez-Alba O; Cianférani S; Scott CJ; van Delft FL; Chudasama V; Albada B
Bioconjug Chem; 2023 Dec; 34(12):2215-2220. PubMed ID: 37962868
[TBL] [Abstract][Full Text] [Related]
5. Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager.
Yang Z; Hou Y; Grande G; Cho JH; Wang C; Shi Y; Zak J; Wan Y; Qin K; Liu D; Teijaro JR; Lerner RA; Wu P
Nat Biomed Eng; 2024 May; ():. PubMed ID: 38693431
[TBL] [Abstract][Full Text] [Related]
6. Inefficient transcription is a production bottleneck for artificial therapeutic BiTE® proteins.
Jerabek T; Burkhart M; Goetz S; Greck B; Menthe A; Neef R; Otte K
N Biotechnol; 2024 Mar; 79():91-99. PubMed ID: 38154615
[TBL] [Abstract][Full Text] [Related]
7. Programmable multispecific DNA-origami-based T-cell engagers.
Wagenbauer KF; Pham N; Gottschlich A; Kick B; Kozina V; Frank C; Trninic D; Stömmer P; Grünmeier R; Carlini E; Tsiverioti CA; Kobold S; Funke JJ; Dietz H
Nat Nanotechnol; 2023 Nov; 18(11):1319-1326. PubMed ID: 37591933
[TBL] [Abstract][Full Text] [Related]
8. Design and engineering of bispecific antibodies: insights and practical considerations.
Madsen AV; Pedersen LE; Kristensen P; Goletz S
Front Bioeng Biotechnol; 2024; 12():1352014. PubMed ID: 38333084
[TBL] [Abstract][Full Text] [Related]
9. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
10. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
11. A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia.
Burke A; Borot F; Du X; Churchill M; Ding J; Grass AM; DeSouza P; Ali AM; Mukherjee S
Oncogene; 2023 Jan; 42(1):26-34. PubMed ID: 36357573
[TBL] [Abstract][Full Text] [Related]
12. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
13. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
14. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
